key: cord-1041161-1q8972uo authors: Hu, F.; Chen, J.; Chen, H.; Zhu, J.; Wang, C.; Ni, H.; Cheng, J.; Cao, P.; Hu, X. title: Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.20.20107607 sha: 6d84f3d2948f9450da4d42ebc266b6ec89e924e7 doc_id: 1041161 cord_uid: 1q8972uo Chansu and its major active constituent of bufalin have been reported to have broad-spectrum antiviral effects. This study aims to assess the efficacy of Chansu injection in treating patients with severe COVID-19. The patients diagnosed as severe or critical COVID-19 in The First People's Hospital of Jiangxia District, Wuhan, China from February 5 to March 5, 2020 were randomly allocated in a 1:1 ratio to receive general treatment plus Chansu injection or only general treatment as the control group. The treatment course was 7 days. The changes of PaO2/FiO2 and ROX index indicating respiratory function, the white blood cell (WBC) count, peripheral blood mononuclear lymphocyte (PBML) count, respiratory support step-down time (RSST), and safety indicators for the 7th day were retrospectively analyzed. After 7 days treatment, the oxygenation index was improved in 20 of 21 patients (95.2%) in the treatment group, as compared with 13 of 19 patients (68.4%) in the control group. The PaO2/FiO2 and ROX indices in the treatment group (mean, 226.27 and 14.01 respectively) were significantly higher than the control group (mean, 143.23 and 9.64 respectively). The RSST was 1 day shorter in the treatment group than the control group. Multivariate regression analysis suggested that Chansu injection contributed the most to the outcome of PaO2/FiO2. No obvious adverse effects were observed. Preliminary data showed that Chansu injection had apparent efficacy in treating patients with severe COVID-19. have little effects on severe COVID-19 patients in clinical trials [5] . Based on China's anti-epidemic experience during the outbreak in Wuhan, traditional Chinese medicine might play an important role in the treatment of COVID-19. Chansu (Cinobufacini), aqueous extracts from the skin and parotid venom glands of the toad Bufo bufo gargarizans Cantor has been widely used in China as an cardiotonic, anodyne, antimicrobial, antineoplastic, and local anesthetic agent for thousands of years [6, 7] . In the recent years, Chansu (in dosage forms of injection, capsules, oral solution and tablets) has been approved by the Chinese State Food and Drug Administration (SFDA) and widely used in clinical cancer and chronic hepatitis B therapy in China [8, 9] . Previous studies found that, bufalin, the major active constituent by targeting the ATP1A1-mediated Src signaling pathway [10] , which also plays a critical role in Ebola and respiratory syncytial virus (RSV) entry into host cells [11, 12] . Based on these findings, Chansu injection was empirically applied to patients with severe COVID-19. Controlled studies are difficult to perform in an epidemic of such a life threatening condition. We present the results from a randomized, preliminary clinical study that evaluated the effect of adding Chansu injection to a general treatment in patients with severe COVID-19. This study preliminary evaluated the efficacy and safety of Chansu injection for severe COVID-19 patients infected by SARS-CoV-2 (trial registration: ChiCTR2000030704). A total of 50 patients were assessed for eligibility and randomly allocated into general treatment (the control group) or general treatment plus Chansu injection group (the treatment group) in a 1:1 ratio. Ten patients were excluded from the final analysis, including 3 patients in the treatment group and 6 patients in the control group transferring to another hospital for further treatment, and 1 patient in the treatment group failed to re-examination the indicators on schedule. The remaining 40 patients including 21 in the treatment group and 19 in the control group were included for statistical analysis (Figure 1 ). Of the 40 participants, 24 (60%) were male. The median age was 61.5 years old (interquartile range [IQR] , 51.0 to 71.0 years) with most patients (82.5%) >50 years old. At least one third of the patients have one or more basic diseases. The median time from onset to treatment was 6 days (IQR, 4.0 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CI, -7.56 to -2.94 for ROX), while no significant differences were found in the control group receiving only general treatment (P > 0.05). The PaO2/FiO2 and ROX index were improved in 20 patients (95.2%) in the treatment group, as compared with 13 (68.4%) and 14 (73.7%) patients in the control group (Table 2 ). These results indicated that most severe COVID-19 patients benefited from Chansu injection, while general treatment with empirical antiviral therapy such as paramivir, arbidol and interferon α, standard glucocorticoid therapy or other symptom relievers and oxygen therapy had little effect on severe COVID-19 patients. COVID-19 patients usually have normal or decreased WBC and decreased PBML. For the secondary outcomes of WBC and PBML, no obvious improvement was observed after 7 days treatment in both groups (P > 0.05). RSST is the time needed for the patients to transform from advanced respiratory support to low respiratory support. The shorter RSST is associated with the faster prognosis of patients' respiratory function. The median of RSST was 5.0 (IQR, 4.0 to 6.0) days in the treatment group, 1 day shorter than that in the control group (median: 6.0 days, IQR: 5.0 to 8.0 days) ( Table 2) . Table 2 Chansu injection contributes the most to the primary outcome of PaO2/FiO2 Univariate linear regression analyses were performed on the patients' baseline characteristics, PaO2/FiO2, ROX index, WBC and PBML on Day 1, and treatment interventions to screen out All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20107607 doi: medRxiv preprint variables with regression coefficients statistically significant. Four characteristics: the PaO2/FiO2 and PBML on Day 1, the initial respiratory support mode and Chansu injection affected PaO2/FiO2 on Day 7 statistically (P < 0.05). To determine the main variables affecting the primary outcome of PaO2/FiO2 on Day 7, multivariate regression analysis was applied. The PaO2/FiO2 on Day 1, the initial respiratory support mode and Chansu injection were further confirmed that could affect the primary outcome of PaO2/FiO2 on Day 7 statistically (P < 0.05). Among them, Chansu injection contributed to the most to the regression model (Beta = 0.486) ( Table 3) . Table 3 Safety Table S1 ). This indicated that the dose of Chansu injection used in this study is safe for severe COVID-19 patients. At present, no approved targeted therapeutics is available for COVID-19 and the treatment recommendations are largely empirical. Chansu is a kind of traditional Chinese medicine extracted from the skin and parotid glands of the toad, which has been approved by SFDA for cancer and antiviral therapy in China. In this study, we evaluated the effect of Chansu plus general treatment in patients with severe COVID-19 in a randomized, preliminary clinical trial. This randomized trial found that, compared with general treatment alone, Chansu injection added to general treatment significantly improved the primary outcomes of PaO2/FiO2 and ROX index in patients with severe COVID-19 after 7 days treatment. General treatment with empirical antiviral therapy such as paramivir, arbidol and interferon α, standard glucocorticoid therapy or other symptom relievers and oxygen therapy had little effect on severe COVID-19 patients. From clinical experience, we found that patients' respiratory function status, such as SpO2, PaO2/FiO2, and ROX index are more direct indicators of an improvement of this disease. In addition, the median RSST needed for the patients in the treatment group is 5.0 days, about one day shorter than the control All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20107607 doi: medRxiv preprint group. Multivariate regression analysis suggested that, among various variables, Chansu injection contributed the most to the primary outcomes of the patients in the treatment group. The main active ingredients of Chansu include bufalin, resibufogenin and cinobufagin, etc. Researchers have found that Chansu has various activities including anti-inflammatory, antiinfection and immunomodulatory [13] [14] [15] . Recent studies reported that Chansu or its active ingredient bufalin shows obvious anti-HBV activities and can inhibit infection of cells with MERS-CoV, Ebola, RSV, MHV, FIPV, and VSV [8] [9] [10] . The mechanism of Chansu inhibiting coronavirus entry into host cells might be related to ATP1A1-mediated Src signaling pathway [8] [9] [10] . Recently, researchers identified ATPases as one of the target of SARS-CoV-2 by interacting with Nsp6 using affinity-purification mass spectrometry method [16] . However, how the coronavirus interacts with ATPases needs further investigation. The side effects caused by Chansu are mainly related to its cardiac glycoside property [17] . This clinical trial conducted in such an emergency has several limitations. Firstly, the trial was not blinded, which might influence clinical decision-making. Secondly, because of limited conditions, the effect of virologic clearance was not tested after 7 days treatment. We can only use the outcomes of respiratory function such as PaO2/FiO2 and ROX index to evaluate the efficacy of Chansu injection. Thirdly, some patients had a history of out-of-hospital treatment, leading to the inconsistency of disease course. Interventions not being able to carried out at the same time after the patients transformed from mild symptoms to severe symptoms may lead to biased results. Other limitations include a small sample size and limited long-term outcome follow-up. In conclusion, we found that Chansu has apparent efficacy in treating severe COVID-19 in this preliminary study. It can improve the patients' respiratory function significantly. These promising early data provide a reference for the treatment of severe COVID-19. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Primary outcomes include PaO2/FiO2 and ROX index (ROX=SpO2/(FiO2*RR)). Secondary outcomes include white blood cell (WBC) count, peripheral blood mononuclear lymphocyte (PBML) count and respiratory support step-down time (RSST). Four respiratory supports of noninvasive ventilation, high-flow oxygen therapy, oxygen mask, and oxygen support with nasal duct gradually weakens for the patients. Therefore, RSST is defined as the transition time from advanced respiratory support to low respiratory support after enrollment, or the time required for FiO2 to decrease by 50%. Successful respiratory support transition is considered if SpO2 remained ≥94% and the increase of RR did not exceed 20%. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20107607 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20107607 doi: medRxiv preprint A Novel Coronavirus from Patients with Pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characteristics of and important lessonsfrom the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection Toad Glandular Secretions and Skin Extractions as Anti-Inflammatory and Anticancer Agents ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells Elucidation of the Ebola Virus VP24 Cellular Interactome and Disruption of Virus Biology through Targeted Inhibition of Host-Cell Protein Function The alpha-1 subunit of the Na+ Cinobufocini inhibits NF-B and COX-2 activation Immunomodulatory effects of cinobufagin isolated from ChanSu on activation and cytokines secretion of immunocyte in vitro A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity This work was supported by a project funded by the Priority Academic Program Development of